Cure & Advancements/July 8, 2026/2 min read

The Missing Conversation: What We Don't Know About Informed Consent for Pig Islet Transplants

Researchers reviewed years of published studies on porcine islet xenotransplantation for Type 1 diabetes and found a surprising gap: there's almost no guidance on how to properly inform patients before they participate in these experimental procedures.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsimmunotherapyadvancements

Key takeaways

Porcine islet xenotransplantation—transplanting insulin-producing cells from pigs into people with Type 1 diabetes—is being explored as a potential treatment, but clinical trials remain rare and scattered.
A new review found only 7 published articles addressing informed consent for this procedure, despite decades of research since 1990.
The absence of clear, published guidance on informed consent raises important questions about how patients are being educated before enrolling in these experimental studies.
Researchers emphasize the need for more scholarly discussion and standardized approaches to consent in xenotransplantation research.

An Emerging Treatment With an Information Gap

Porcine islet xenotransplantation—the transplantation of insulin-producing cells from pigs into people with Type 1 diabetes—represents one of several experimental approaches being investigated to restore or replace lost insulin production. While the scientific research in this area has been ongoing since at least 1990, clinical studies using this approach have been conducted only sporadically over the past three decades.

Despite this long history of research, a new review published in Xenotransplantation found a striking gap: there is virtually no published literature describing best practices or standards for informed consent in porcine islet xenotransplantation studies.

What the Review Found

Researchers searched four major medical literature databases—PubMed, SCOPUS, EMBASE, and CINAHL—for peer-reviewed articles published between January 1990 and May 2025 that addressed islet xenotransplantation and informed consent. They used various combinations of search terms to cast a wide net.

Out of 134 sources initially identified, only 7 articles met the criteria for inclusion in the final review. This scarcity highlights what the authors call 'a lack of literature describing informed consent for islet xenotransplantation' and points to 'a scarcity of scholarly discourse and published guidance' on this topic.

Why This Matters

Informed consent is a cornerstone of ethical research and medical practice. It means that before a person enrolls in a clinical trial or receives an experimental treatment, they must be given clear, understandable information about what the procedure involves, what risks it carries, what benefits it might offer, and what alternatives exist.

When there is little published guidance on informed consent for a particular procedure, it can lead to inconsistency in how different research teams educate and obtain permission from participants. It can also leave patients and families without access to standardized, evidence-based information about what to expect.

This review does not evaluate whether current informed consent practices in xenotransplantation studies are adequate or inadequate—only that the published literature on the topic is sparse. The authors call for more scholarly discussion and clearer published guidance to help standardize and strengthen informed consent processes in this field.

Evidence label

Source: Xenotransplantation. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.